Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Spectrum (SPPI) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Spectrum between March 17, 2022 to September 22, 2022 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Br ...

SAN FRANCISCO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead plaintiff was disqualified on August 4, 2025. The new deadline to apply is September 24, 2025. Importantly, (1) investors who purchased Spectrum (SPPI) common shares on the open market during the Class Period and (2) ...

Accessibility StatementSkip Navigation PHILADELPHIA, Sept. 23, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022(the "Class Period"). Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Pe ...

NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the “Class Period”), of the important September 24, 2025 lead plaintiff deadline. The lead plaintiff process was reopened by the Court. SO WHAT: If you purchased Spectrum Pharmaceuticals common stock during the Class Period you may be entitled to compensation ...

SAN FRANCISCO, Sept. 21, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead plaintiff was disqualified on August 4, 2025. The new deadline to apply is September 24, 2025. Importantly, (1) investors who purchased Spectrum (SPPI) common shares on the open market during the Class Period and (2) ...

集体诉讼案件 - 罗森律师事务所提醒在2022年5月12日至2022年9月22日期间购买Spectrum Pharmaceuticals公司普通股的投资者注意2025年9月24日的首席原告截止日期 [1] - 投资者可能有权通过风险代理费用安排获得补偿而无需支付任何自付费用 [2] - 投资者可通过指定网址或电话联系Phillip Kim律师加入集体诉讼 首席原告动议必须在2025年9月24日前向法院提出 [3] 诉讼案由 - 指控Spectrum Pharmaceuticals就其PINNACLE研究发表虚假或误导性声明 该研究涉及用于治疗特定肺癌患者的poziotinib药物临床实验 [5] - 当真实细节进入市场时 投资者遭受了损失 [5] 律师事务所资质 - 罗森律师事务所专注于证券集体诉讼和股东派生诉讼 在全球代表投资者 [4] - 2017年获得ISS证券集体诉讼服务结算数量排名第一 2013年以来每年保持前四名 [4] - 2019年单年为投资者追回4.38亿美元 累计为投资者追回数亿美元 [4] - 2020年创始合伙人Laurence Rosen被law360评为原告律师界泰斗 [4] 案件程序状态 - 目前尚未确认集体诉讼资格 在确认前投资者需自行保留律师 [6] - 投资者可选择自行聘请律师 或保持缺席集体成员身份 未来获得赔偿的资格不依赖于担任首席原告 [6]

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the “Class Period”), of the important September 24, 2025 lead plaintiff deadline. The lead plaintiff process was reopened by the Court. SO WHAT: If you purchased Spectrum Pharmaceuticals common stock during the Class Period you may be entitled to compensation ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Spectrum (SPPI) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Spectrum between March 17, 2022 to September 22, 2022 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Br ...

SAN FRANCISCO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead plaintiff was disqualified on August 4, 2025. The new deadline to apply is September 24, 2025. Importantly, (1) investors who purchased Spectrum (SPPI) common shares on the open market during the Class Period and (2) ...

PHILADELPHIA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (“Spectrum” or the “Company”) on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the “Class Period”). Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, ...